Hosted on MSN8h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Arrowhead price target raised to $80 from $60 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Sarepta price target lowered to $75 from $80 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...
Sarepta price target lowered to $202 from $205 at Needham
Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with clear long-term ...